UNSPSC 51352007: Norelgestromin

This classification denotes a therapeutic progestin with the molecular formula C21H29NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R0TAY3X631, chemically known as 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, oxime, (8-alpha,9-beta,10-alpha,13-alpha,14-beta)- but generally known as norelgestromin, which bears US NIH Compound Identifier 62930. European Medicines Agency schedules Norelgestromin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20476.

UNSPSC 51352007 Norelgestromin is a Commodity code for a specific progestin pharmaceutical active ingredient. State and local government procurement under this code focuses on acquiring generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing agreements that aggregate demand across participating jurisdictions. The work involves manufacturers supplying products to authorized pharmaceutical wholesalers for distribution to state agencies, local health departments, schools, correctional facilities, and other public entities. Issuing bodies include state departments of administration and health, counties, cities, and special-purpose health districts accessing cooperative purchasing vehicles to manage pharmaceutical costs and ensure supply chain compliance.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving Minnesota, Oregon, and other participating states and localities. Manufacturers must provide comprehensive pricing for identified pharmaceutical products with specific National Drug Codes, maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and maintain insurance coverage including $5 million commercial general liability and $2 million network security and professional liability. Products must be available in the marketplace by May 15, 2026, with awarded agreements effective July 1, 2026. Evaluation weights pricing competitiveness at 75 percent, with the remainder distributed across fixed pricing, administrative compliance, EDI capability, and willingness to accept a 3 percent administrative fee. The contract term is two years for new responders with optional extensions, or alignment with existing agreement expiration dates through June 30, 2028 for incumbent vendors.